{
  "id": 81305,
  "title": "Encube Ethicals files papers with SEBI for ₹3,000 cr IPO",
  "url": "https://urgent.news/2026/08/03/encube-ethicals-files-papers-with-sebi-for-3-000-cr-ipo",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-03T10:55:31.000Z",
  "source": {
    "name": "Hindu BusinessLine",
    "slug": "hindu-businessline",
    "url": "https://www.thehindubusinessline.com/companies/encube-ethicals-files-papers-with-sebi-for-3000-cr-ipo/article71300771.ece"
  },
  "original_language": "en",
  "account": "Specialty pharmaceutical firm Encube Ethicals has submitted preliminary documents to the capital markets regulator SEBI for a significant IPO valued at ₹3,000 crore. The Mumbai-based company's initial public offering is entirely an offer for sale by its founder Mehul Madhusudan Shah and current investor Frontier Investment Holdings Pte. Ltd, as outlined in their Draft Red Herring Prospectus (DRHP) filed on Friday. Given that this is an OFS, the company will not receive any funds from the public sale; instead, the proceeds will be allocated to the selling shareholders.\n\nEstablished in 1995, Encube Ethicals operates as a global platform for specialty pharmaceutical formulations, boasting expertise in complex topical and transdermal dosage forms. As of March 31, 2026, the company serves a diverse clientele across 50 countries, including markets such as the United States, UK, and Europe, alongside India. The company's manufacturing operations are accredited by 11 regulatory bodies, encompassing the US Food and Drug Administration (USFDA), EU Good Manufacturing Practice (GMP), Japan Pharmaceuticals and Medical Devices Agency (PMDA), Health Canada, Brazil's National Agency for Sanitary Surveillance (ANVISA), and the Therapeutic Goods Administration (TGA) of Australia. Supported by a workforce of 1,684 employees as of the same date, Encube Ethicals provides comprehensive development and manufacturing services to more than 160 pharmaceutical companies across 50 nations.\n\nFinancially, the company reported a revenue of ₹1,848.7 crore and a net profit of ₹436.7 crore during the financial year 2026 (FY26). The shares are set to be listed on both the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE). JM Financial, Axis Capital, and Kotak Mahindra Capital Company have been appointed as the book running lead managers, while MUFG Intime India serves as the registrar for the issue. The shares will be issued in English and must adhere to the platform's community guidelines.",
  "summary": "On the financial front, its revenue from operations was at ₹1,848.7 crore and its net profit at ₹436.7 crore during FY26",
  "key_points": [
    "Encube Ethicals files ₹3,000 cr IPO documents with SEBI.",
    "Founder Mehul Madhusudan Shah and investor Frontier Investment Holdings Pte. Ltd. sell shares.",
    "Company operates globally, serves 50 countries."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Hindu BusinessLine",
        "title": "Assetz files IPO papers with SEBI via confidential route, plans ₹1,200-cr issue",
        "url": "https://urgent.news/2026/08/02/assetz-files-ipo-papers-with-sebi-via-confidential-route-plans-1-200",
        "published": "2026-08-02T08:19:21.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}